Generation and characterization of two human induced pluripotent stem cell (hiPSC) lines homozygous for the Apolipoprotein e4 (APOE4) risk variant—Alzheimer's disease (ASUi005-A) and healthy non-demented control (ASUi006-A)

Nicholas Brookhouser,Ping Zhang,Richard Caselli,Jean J Kim,David A Brafman

doi:10.1016/j.scr.2018.09.007

Nicholas Brookhouser, Ping Zhang + Show 3 more

Open Access

https://doi.org/10.1016/j.scr.2018.09.007

Copy DOI

Abstract

Although the majority of late-onset Alzheimer's disease (AD) patients are labeled sporadic, multiple genetic risk variants have been identified, the most powerful and prevalent of which is the e4 variant of the Apolipoprotein E (APOE) gene. Here, we generated human induced pluripotent stem cell (hiPSC) lines from the peripheral blood mononuclear cells (PBMCs) of a clinically diagnosed AD patient [ASUi005-A] and a non-demented control (NDC) patient [ASUi006-A] homozygous for the APOE4 risk allele. These hiPSCs maintained their original genotype, expressed pluripotency markers, exhibited a normal karyotype, and retained the ability to differentiate into cells representative of the three germ layers.Resource tableUnlabelled TableUnique stem cell lines identifierASUi005-AASUi006-AAlternative names of stem cell linesASU-161ASU-487InstitutionArizona State University; Tempe, AZ; USAContact information of distributorDavid Brafman, David.Brafman@asu.eduType of cell linesiPSCOriginHumanCell sourceHuman peripheral blood mononuclear cells (PBMCs)ClonalityClonalMethod of reprogrammingCytoTune®-iPS 2.0 Reprogramming SystemMultiline rationaleAge-matched Alzheimer's disease and non-demented control hiPSC lines homozygous for the APOE 4 risk factorGene modificationNoType of modificationN/AAssociated diseaseAlzheimer's diseaseGene/locusApolipoprotein E (APOE)Method of modificationN/AName of transgene or resistanceN/AInducible/constitutive systemN/ADate archived/stock dateMarch 2018Cell line repository/bankNot applicableEthical approvalMayo Clinic Institutional Review Board; IRB # 15-008674

Highlights

The majority of late-onset Alzheimer's disease (AD) patients are labeled sporadic, multiple genetic risk variants have been identified, the most powerful and prevalent of which is the e4 variant of the Apolipoprotein E (APOE) gene
Polymorphisms in the Apolipoprotein (APOE) gene have been identified as the most prevalent of the risk factors associated with sporadic Alzheimer's disease (AD)
Genome-wide association studies (GWAS) studies have identified several risk factors associated with increased probability of sporadic Alzheimer's disease (SAD) onset (Bettens et al, 2010)

Summary

Introduction

The majority of late-onset Alzheimer's disease (AD) patients are labeled sporadic, multiple genetic risk variants have been identified, the most powerful and prevalent of which is the e4 variant of the Apolipoprotein E (APOE) gene. ASUi005-A ASUi006-A ASU-161 ASU-487 Arizona State University; Tempe, AZ; USA David Brafman, David.Brafman@asu.edu iPSC Human Human peripheral blood mononuclear cells (PBMCs) Clonal CytoTune®-iPS 2.0 Reprogramming System Age-matched Alzheimer's disease and non-demented control hiPSC lines homozygous for the APOE 4 risk factor No N/A Alzheimer's disease Apolipoprotein E (APOE) N/A N/A N/A March 2018 Not applicable Mayo Clinic Institutional Review Board; IRB # 15-008674 Polymorphisms in the Apolipoprotein (APOE) gene have been identified as the most prevalent of the risk factors associated with sporadic Alzheimer's disease (AD).

Results

Conclusion